Anticoagulant therapy for splanchnic vein thrombosis: recent updates for patients with liver cirrhosis

References

• Myers K, Hannah P. Anatomy of veins and lymphatics. In: Myers K, Hannah P, editors. Manual of venous and lymphatic diseases. London UK: Taylor & Francis Ltd; 2018. p. 13–38.
   Google Scholar
• Akhondi H, Ganjali S, Nagalli S. In: Splanchnic Venous Thrombosis. 2022 Jan 19. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan–. PMID: 31985963.
   Google Scholar
• Thatipelli MR, McBane RD, Hodge DO, et al. Survival and recurrence in patients with splanchnic vein thromboses. Clin Gastroenterol Hepatol. 2010;8(2):200–205.
   PubMed Web of Science ®Google Scholar
• Galante A, De Gottardi A. Portal vein thrombosis: an overview of current treatment options. Acta Gastroenterol Belg. 2021;84(2):327–332.
   PubMed Web of Science ®Google Scholar
• Riva N, Ageno W. Clinical manifestations and imaging tools in the diagnosis of splanchnic and cerebral vein thromboses. Thromb Res. 2018;163:252–259.
   PubMed Web of Science ®Google Scholar
• Lisman T, Caldwell SH, Intagliata NM. Haemostatic alterations and management of haemostasis in patients with cirrhosis. J Hepatol. 2022;76(6):1291–1305.
   PubMed Web of Science ®Google Scholar
• Violi F, Basili S, Raparelli V, et al. Patients with liver cirrhosis suffer from primary haemostatic defects? Fact or fiction? J Hepatol. 2011;55(6):1415–1427.
   PubMed Web of Science ®Google Scholar
• Afdhal N, McHutchison J, Brown R, et al. Thrombocytopenia associated with chronic liver disease. J Hepatol. 2008;48(6):1000–1007.
   PubMed Web of Science ®Google Scholar
• Stockschlaeder M, Schneppenheim R, Budde U. Update on von Willebrand factor multimers: focus on high-molecular-weight multimers and their role in hemostasis. Blood Coagul Fibrinolysis. 2014;25(3):206–216.
   PubMed Web of Science ®Google Scholar
• Zanetto A, Campello E, Bulato C, et al. Increased platelet aggregation in patients with decompensated cirrhosis indicates higher risk of further decompensation and death. J Hepatol. 2022;77(3):660–669.
   PubMed Web of Science ®Google Scholar
• Zanetto A, Campello E, Burra P, et al. Increased platelet ratio in patients with decompensated cirrhosis indicates a higher risk of portal vein thrombosis. Liver Int. 2023;43(1):155–159.
   PubMed Web of Science ®Google Scholar
• Tripodi A, Mannucci PM. The coagulopathy of chronic liver disease. N Engl J Med. 2011;365(2):147–156.
   PubMed Web of Science ®Google Scholar
• Leebeek FW, Eikenboom JC. Von Willebrand’s Disease. N Engl J Med. 2016;375(21):2067–2080.
   PubMed Web of Science ®Google Scholar
• Gatt A, Riddell A, Calvaruso V, et al. Enhanced thrombin generation in patients with cirrhosis-induced coagulopathy. J Thromb Haemost. 2010;8(9):1994–2000.
   PubMed Web of Science ®Google Scholar
• Zermatten MG, Fraga M, Moradpour D, et al. Hemostatic Alterations in Patients With Cirrhosis: From Primary Hemostasis to Fibrinolysis. Hepatology. 2020;71(6):2135–2148.
   PubMed Web of Science ®Google Scholar
• Ambrosino P, Tarantino L, Di Minno G, et al. The risk of venous thromboembolism in patients with cirrhosis. A systematic review and meta-analysis. Thromb Haemost. 2017;117(1):139–148.
   PubMed Web of Science ®Google Scholar
• Campello E, Zanetto A, Bulato C, et al. Coagulopathy is not predictive of bleeding in patients with acute decompensation of cirrhosis and acute-on-chronic liver failure. Liver Int. 2021;41(10):2455–2466.
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. EASL Clinical Practice Guidelines on prevention and management of bleeding and thrombosis in patients with cirrhosis. J Hepatol. 2022;76(5):1151–1184.
   PubMed Web of Science ®Google Scholar
• Naymagon L, Tremblay D, Zubizarreta N, et al. Safety, Efficacy, and Long-Term Outcomes of Anticoagulation in Cirrhotic Portal Vein Thrombosis. Dig Dis Sci. 2021;66(10):3619–3629.
   PubMed Web of Science ®Google Scholar
• Violi F, Corazza GR, Caldwell SH, et al. Portal vein thrombosis relevance on liver cirrhosis: Italian Venous Thrombotic Events Registry. Intern Emerg Med. 2016;11(8):1059–1066.
   PubMed Web of Science ®Google Scholar
• Francoz C, Valla D, Durand F. Portal vein thrombosis, cirrhosis, and liver transplantation. J Hepatol. 2012;57(1):203–212.
   PubMed Web of Science ®Google Scholar
• Driever EG, Magaz M, Adelmeijer J, et al. The portal vein in patients with cirrhosis is not an excessively inflammatory or hypercoagulable vascular bed, a prospective cohort study. J Thromb Haemost. 2022;20(9):2075–2082.
   PubMed Web of Science ®Google Scholar
• Shalaby S, Simioni P, Campello E, et al. Endothelial Damage of the Portal Vein is Associated with Heparin-Like Effect in Advanced Stages of Cirrhosis. Thromb Haemost. 2020;120(8):1173–1181.
   PubMedGoogle Scholar
• Nery F, Carneiro P, Correia S, et al. Systemic inflammation as a risk factor for portal vein thrombosis in cirrhosis: a prospective longitudinal study. Eur J Gastroenterol Hepatol. 2021;33(1SSuppl 1):e108–e113.
   PubMedGoogle Scholar
• Turon F, Driever EG, Baiges A, et al. Predicting portal thrombosis in cirrhosis: A prospective study of clinical, ultrasonographic and hemostatic factors. J Hepatol. 2021;75(6):1367–1376.
   PubMed Web of Science ®Google Scholar
• Tsochatzis EA, Senzolo M, Germani G, et al. Systematic review: portal vein thrombosis in cirrhosis. Aliment Pharmacol Ther. 2010;31(3):366–374.
   PubMed Web of Science ®Google Scholar
• Villa E, Cammà C, Marietta M, et al. Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology. 2012;143(5):1253–1260.e4.
   PubMed Web of Science ®Google Scholar
• Acosta S, Alhadad A, Svensson P, et al. Epidemiology, risk and prognostic factors in mesenteric venous thrombosis. Br J Surg. 2008;95(10):1245–1251.
   PubMed Web of Science ®Google Scholar
• De Stefano V, Martinelli I. Splanchnic vein thrombosis: clinical presentation, risk factors and treatment. Intern Emerg Med. 2010;5(6):487–494.
   PubMed Web of Science ®Google Scholar
• Valeriani E, Riva N, Di Nisio M, et al. Splanchnic vein thrombosis: Current Perspectives. Vasc Health Risk Manag. 2019;15:449–461.
   PubMed Web of Science ®Google Scholar
• Sogaard KK, Astrup LB, Vilstrup H, et al. Portal vein thrombosis; risk factors, clinical presentation and treatment. BMC Gastroenterol. 2007;7:34.
   PubMed Web of Science ®Google Scholar
• Caiano LM, Riva N, Carrier M, et al. Treatment of portal vein thrombosis: an updated narrative review. Minerva Med. 2021;112(6):713–725.
   PubMed Web of Science ®Google Scholar
• Odriozola A, Puente A, Cuadrato A, et al. Portal Vein Thrombosis in the Setting of Cirrhosis: A Comprehensive Review. J Clin Med. 2022;11(21):6435.
   PubMed Web of Science ®Google Scholar
• Riva N, Ageno W, Schulman S, et al. Clinical history and antithrombotic treatment of incidentally detected splanchnic vein thrombosis: a multicentre, international prospective registry. Lancet Haematol. 2016;3(6):e267–75.
   PubMed Web of Science ®Google Scholar
• McMurry H, Sabile JMG, Elstrott B, et al. Clinical predictors for thrombus progression in cirrhotic patients with untreated splanchnic vein thrombosis. Thromb Res. 2022;216:1–7.
   PubMed Web of Science ®Google Scholar
• Ageno W, Riva N, Schulman S, et al. Long-term Clinical Outcomes of Splanchnic Vein Thrombosis: Results of an International Registry. JAMA Intern Med. 2015;175(9):1474–1480.
   PubMed Web of Science ®Google Scholar
• Senzolo M, Riva N, Dentali F, et al. Long-Term Outcome of Splanchnic Vein Thrombosis in Cirrhosis. Clin Transl Gastroenterol. 2018;9(8):176.
   PubMedGoogle Scholar
• Candeloro M, Valeriani E, Monreal M, et al. Anticoagulant therapy for splanchnic vein thrombosis: an individual patient data meta-analysis. Blood Adv. 2022;6(15):4516–4523.
   PubMed Web of Science ®Google Scholar
• Pettinari I, Vukotic R, Stefanescu H, et al. Clinical impact and safety of anticoagulants for portal vein thrombosis in cirrhosis. Am J Gastroenterol. 2019;114:258–266.
   PubMed Web of Science ®Google Scholar
• Amitrano L, Guardascione MA, Scaglione M, et al. Splanchnic vein thrombosis and variceal rebleeding in patients with cirrhosis. Eur J Gastroenterol Hepatol. 2012;24:1381–1385.
   PubMed Web of Science ®Google Scholar
• Wang L, Guo X, Xu X, et al. Anticoagulation Favors Thrombus Recanalization and Survival in Patients With Liver Cirrhosis and Portal Vein Thrombosis: Results of a Meta-Analysis. Adv Ther. 2021;38(1):495–520.
   PubMed Web of Science ®Google Scholar
• Ghazaleh S, Beran A, Aburayyan K, et al. Efficacy and safety of anticoagulation in non-malignant portal vein thrombosis in patients with liver cirrhosis: a systematic review and meta-analysis. Ann Gastroenterol. 2021;34(1):104–110.
   PubMed Web of Science ®Google Scholar
• Valeriani E, Di Nisio M, Riva N, et al. Anticoagulant Treatment for Splanchnic Vein Thrombosis in Liver Cirrhosis: A Systematic Review and Meta-Analysis. Thromb Haemost. 2021;121(7):867–876.
   PubMedGoogle Scholar
• de Franchis R, Bosch J, Garcia-Tsao G, et al. Baveno VII - Renewing consensus in portal hypertension. J Hepatol. 2022 Apr;76(4):959–974.
   PubMed Web of Science ®Google Scholar
• Delgado MG, Seijo S, Yepes I, et al. Efficacy and safety of anticoagulation on patients with cirrhosis and portal vein thrombosis. Clin Gastroenterol Hepatol. 2012;10(7):776–783.
   PubMed Web of Science ®Google Scholar
• Cui SB, Shu RH, Yan SP, et al. Efficacy and safety of anticoagulation therapy with different doses of enoxaparin for portal vein thrombosis in cirrhotic patients with hepatitis B. Eur J Gastroenterol Hepatol. 2015;27(8):914–919.
   PubMed Web of Science ®Google Scholar
• Napolitano M, Saccullo G, Marietta M, et al. Platelet cut-off for anticoagulant therapy in thrombocytopenic patients with blood cancer and venous thromboembolism: an expert consensus. Blood Transfus. 2019;17(3):171–180.
   PubMed Web of Science ®Google Scholar
• Senzolo M, Piano S, Shalaby S, et al. Comparison of Fondaparinux and Low-Molecular-Weight Heparin in the Treatment of Portal Vein Thrombosis in Cirrhosis. Am J Med. 2021;134(10):1278–1285.e2.
   PubMed Web of Science ®Google Scholar
• Senzolo M, Garcia-Tsao G, García-Pagán JC. Current knowledge and management of portal vein thrombosis in cirrhosis. J Hepatol. 2021;75(2):442–453.
   PubMed Web of Science ®Google Scholar
• Gatt A, Chen D, Pruthi RK, et al. From vitamin K antagonists to liver international normalized ratio: a historical journey and critical perspective. Semin Thromb Hemost. 2014;40(8):845–851.
   PubMed Web of Science ®Google Scholar
• Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016;149(2):315–352.
   PubMed Web of Science ®Google Scholar
• Di Nisio M, Valeriani E, Riva N, et al. Anticoagulant therapy for splanchnic vein thrombosis: ISTH SSC Subcommittee Control of Anticoagulation. J Thromb Haemost. 2020;18(7):1562–1568.
   PubMed Web of Science ®Google Scholar
• Nagaoki Y, Aikata H, Daijyo K, et al. Efficacy and safety of edoxaban for treatment of portal vein thrombosis following danaparoid sodium in patients with liver cirrhosis. Hepatol Res. 2018;48:51–58.
   PubMed Web of Science ®Google Scholar
• Hanafy AS, Abd-Elsalam S, Dawoud MM. Randomized controlled trial of rivaroxaban versus warfarin in the management of acute non-neoplastic portal vein thrombosis. Vascul Pharmacol. 2019;113:86–91.
   PubMed Web of Science ®Google Scholar
• MH A, WG D, XP T, et al. Efficacy and safety study of direct-acting oral anticoagulants for the treatment of chronic portal vein thrombosis in patients with liver cirrhosis. Eur J Gastroenterol Hepatol. 2020;32: 1395–400.
   Web of Science ®Google Scholar
• Mohan BP, Aravamudan VM, Khan SR, et al. Treatment response and bleeding events associated with anticoagulant therapy of portal vein thrombosis in cirrhotic patients: systematic review and meta-analysis. Ann Gastroenterol. 2020;33:521–527.
   PubMed Web of Science ®Google Scholar
• De Gottardi A, Trebicka J, Klinger C, et al. VALDIG Investigators. Antithrombotic treatment with direct-acting oral anticoagulants in patients with splanchnic vein thrombosis and cirrhosis. Liver Int. 2017;37:694–699.
   PubMed Web of Science ®Google Scholar
• Abbattista M, Capecchi M, Martinelli I. Treatment of unusual thrombotic manifestations. Blood. 2020 Jan 30;135(5):326–334.
   PubMed Web of Science ®Google Scholar
• De Santis A, Moscatelli R, Catalano C, et al. Systemic thrombolysis of portal vein thrombosis in cirrhotic patients: a pilot study. Dig Liver Dis. 2010;42(6):451–455.
   PubMedGoogle Scholar
• Fagiuoli S, Bruno R, Debernardi Venon W, et al. Consensus conference on TIPS management: Techniques, indications, contraindications. Dig Liver Dis. 2017;49(2):121–137.
   PubMedGoogle Scholar
• Northup PG, Garcia-Pagan JC, Garcia-Tsao G, et al. Vascular Liver Disorders, Portal Vein Thrombosis, and Procedural Bleeding in Patients With Liver Disease: 2020 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2021;73(1):366–413.
   PubMed Web of Science ®Google Scholar
• Rodrigues SG, Sixt S, Abraldes JG, et al. Systematic review with meta-analysis: portal vein recanalisation and transjugular intrahepatic portosystemic shunt for portal vein thrombosis. Aliment Pharmacol Ther. 2019;49(1):20–30.
   PubMed Web of Science ®Google Scholar
• Wang Z, Jiang MS, Zhang HL, et al. Is Post-TIPS Anticoagulation Therapy Necessary in Patients with Cirrhosis and Portal Vein Thrombosis? A Randomized Controlled Trial. Radiology. 2016;279(3):943–951.
   PubMed Web of Science ®Google Scholar
• Lv Y, Qi X, He C, et al. Covered TIPS versus endoscopic band ligation plus propranolol for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: a randomised controlled trial. Gut. 2018;67(12):2156–2168.
   PubMed Web of Science ®Google Scholar
• Luo X, Wang Z, Tsauo J, et al. Advanced Cirrhosis Combined with Portal Vein Thrombosis: A Randomized Trial of TIPS versus Endoscopic Band Ligation Plus Propranolol for the Prevention of Recurrent Esophageal Variceal Bleeding. Radiology. 2015;276(1):286–293.
   PubMed Web of Science ®Google Scholar
• Chamarthy MR, Anderson ME, Pillai AK, et al. Thrombolysis and Transjugular Intrahepatic Portosystemic Shunt Creation for Acute and Subacute Portal Vein Thrombosis. Tech Vasc Interv Radiol. 2016;19(1):42–51.
   PubMedGoogle Scholar
• Miñano C, Garcia-Tsao G. Clinical pharmacology of portal hypertension. Gastroenterol Clin North Am. 2010;39(3):681–695.
   PubMed Web of Science ®Google Scholar
• Groszmann RJ, Garcia-Tsao G, Bosch J, et al. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med. 2005;353(21):2254–2261.
   PubMed Web of Science ®Google Scholar
• Sauerbruch T, Wong F. Treatment of Oesophageal Varices in Liver Cirrhosis. Digestion. 2019;99(4):261–266.
   PubMed Web of Science ®Google Scholar
• Cerini F, Gonzalez JM, Torres F, et al. Impact of anticoagulation on upper-gastrointestinal bleeding in cirrhosis. A retrospective multicenter study. Hepatology. 2015;62(2):575–583.
   PubMed Web of Science ®Google Scholar
• Vanbiervliet G, Giudicelli-Bornard S, Piche T, et al. Predictive factors of bleeding related to post-banding ulcer following endoscopic variceal ligation in cirrhotic patients: a case-control study. Aliment Pharmacol Ther. 2010;32(2):225–232.
   PubMed Web of Science ®Google Scholar
• Dueñas E, Cachero A, Amador A, et al. Ulcer bleeding after band ligation of esophageal varices: Risk factors and prognosis. Dig Liver Dis. 2020;52(1):79–83.
   PubMedGoogle Scholar
• Kundumadam S, Phatharacharukul P, Reinhart K, et al. Bleeding After Elective Interventional Endoscopic Procedures in a Large Cohort of Patients With Cirrhosis. Clin Transl Gastroenterol. 2020;11(12):e00288.
   PubMed Web of Science ®Google Scholar
• Bianchini M, Cavani G, Bonaccorso A, et al. Low molecular weight heparin does not increase bleeding and mortality post-endoscopic variceal band ligation in cirrhotic patients. Liver Int. 2018;38(7):1253–1262.
   PubMed Web of Science ®Google Scholar
• Ponthus S, Spahr L, Casini A, et al. Safety of variceal band ligation in patients with cirrhosis and portal vein thrombosis treated with anticoagulant therapy: A retrospective study. Eur J Gastroenterol Hepatol. 2020;32(3):395–400.
   PubMed Web of Science ®Google Scholar
• Guillaume M, Christol C, Plessier A, et al. Bleeding risk of variceal band ligation in extrahepatic portal vein obstruction is not increased by oral anticoagulation. Eur J Gastroenterol Hepatol. 2018;30:563–568.
   PubMed Web of Science ®Google Scholar
• Riva N, Carrier M, Gatt A, et al. Anticoagulation in splanchnic and cerebral vein thrombosis: an international vignette-based survey. Res Pract Thromb Haemost. 2020;4:1192–1202.
   PubMed Web of Science ®Google Scholar